For U.S. Healthcare Professionals       Visit Patient Site
For U.S. Healthcare Professionals

Clinically validated hot flash relief

EQUELLE provided meaningful reductions in daily hot flash frequency as early as Week 41†§

Mean change from baseline in daily hot flash frequency (baseline >8; n=24)

Hot flash frequency chart
Hot flash frequency chart
  • Meaningful reductions in daily hot flash frequency as early as Week 4 that continued declining through Week 8 (P=0.063 vs isoflavone)1
  • Patients receiving EQUELLE experienced approximately 5 fewer hot flashes per day at Week 8 in comparison to baseline1
§In a double-blind, active comparator trial, 102 menopausal women were randomized to receive EQUELLE or soy isoflavones for up to 8 weeks.1

EQUELLE demonstrated 2.5× the hot flash reduction vs placebo in a separate clinical trial2†||

63% reduction in daily hot flash frequency with EQUELLE versus 24% with placebo at Week 12 (P=0.009)2
2.5 times hot flash reduction vs placebo
50 min more sleep per night

EQUELLE improved both sleep time and sleep quality3†¶

Significant improvements in sleep quality from baseline were observed at Week 4 in poor sleepers as measured by the Pittsburgh Sleep Quality Index3**

Sleep quality continued to improve significantly from baseline for the duration of the 12 weeks3**
||
In a multicenter, double-blind, placebo-controlled trial, 160 post-menopausal women were randomized to receive EQUELLE or placebo for up to 12 weeks.2
In a multicenter, double-blind, placebo-controlled trial, 118 perimenopausal or menopausal women were randomized to receive EQUELLE or placebo for up to 12 weeks.3
#
Sleep minutes were calculated using the Motionlogger Micro Watch (a wearable sleep tracker) that patients wore at home for a week at a time to measure changes in sleep.
**
Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), which is a 19-item questionnaire designed to measure sleep disturbances. A higher score on the PSQI indicates greater sleep disturbance.

EQUELLE demonstrated 2.5× the hot flash reduction vs placebo in a separate clinical trial2†||

63% reduction in daily hot flash frequency with EQUELLE versus 24% with placebo at Week 12 (P=0.009)2
2.5 times hot flash reduction vs placebo

EQUELLE improved both sleep time and sleep quality3†¶

Significant improvements in sleep quality from baseline were observed at Week 4 in poor sleepers as measured by the Pittsburgh Sleep Quality Index3**

Sleep quality continued to improve significantly from baseline for the duration of the 12 weeks3**
50 min more sleep per night
||
In a multicenter, double-blind, placebo-controlled trial, 160 post-menopausal women were randomized to receive EQUELLE or placebo for up to 12 weeks.2
In a multicenter, double-blind, placebo-controlled trial, 118 perimenopausal or menopausal women were randomized to receive EQUELLE or placebo for up to 12 weeks.3
#
Sleep minutes were calculated using the Motionlogger Micro Watch (a wearable sleep tracker) that patients wore at home for a week at a time to measure changes in sleep.
**
Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), which is a 19-item questionnaire designed to measure sleep disturbances. A higher score on the PSQI indicates greater sleep disturbance.

EQUELLE improved bothersome vaginal symptoms of menopause3†¶

Change in vaginal symptoms from baseline at Week 12†† (n=58)

Change in vaginal symptoms from baseline graph
• EQUELLE significantly improved vaginal symptoms for patients with 9 or more daily vasomotor symptoms 3
In a multicenter, double-blind, placebo-controlled trial, 118 perimenopausal or menopausal women were randomized to receive EQUELLE or placebo for up to 12 weeks.3
††
In patients with >9 vasomotor symptoms at baseline.

With EQUELLE, patients saw significant improvement in mood swings3†¶

  • Patients with frequent vasomotor symptoms (9 or more per day) saw significant improvement in emotional well-being at Week 12 vs placebo (P=0.049)3‡‡
  • Patients with high vasomotor symptoms (9 or more per day) also showed a significant reduction in anger-hostility vs placebo (P=0.049)3§§
  • This benefit occurred as early as 8 weeks (P=0.019)
  • Both total mood disturbance and vigor-activity were also significantly improved, compared to placebo (P=0.049, P=0.017 respectively)
Significant improvement in mood swings
 
In a multicenter, double-blind, placebo-controlled trial, 118 perimenopausal or menopausal women were randomized to receive EQUELLE or placebo for up to 12 weeks.3
#
As measured by RAND-36, a well-validated health-related quality of life survey.
§§
As measured by Profile of Mood States (POMS-2).
Important Patient Information
Some reports of moderately elevated gastrointestinal effects, such as gas and bloating, were observed in women taking phytoestrogens.

With EQUELLE, patients saw significant improvement in mood swings3†¶

  • Patients with frequent vasomotor symptoms (9 or more per day) saw significant improvement in emotional well-being at Week 12 vs placebo (P=0.049)3‡‡
  • Patients with high vasomotor symptoms (9 or more per day) also showed a significant reduction in anger-hostility vs placebo (P=0.049)3§§
  • This benefit occurred as early as 8 weeks (P=0.019)
  • Both total mood disturbance and vigor-activity were also significantly improved, compared to placebo (P=0.049, P=0.017 respectively)
In a multicenter, double-blind, placebo-controlled trial, 118 perimenopausal or menopausal women were randomized to receive EQUELLE or placebo for up to 12 weeks.3
‡‡
As measured by RAND-36, a well-validated health-related quality of life survey.
§§
As measured by Profile of Mood States (POMS-2).
Significant improvement in mood swings

Important Patient Information

Some reports of moderately elevated gastrointestinal effects, such as gas and bloating, were observed in women taking phytoestrogens.

See the science for yourself

As published in the Journal of Women’s Health
A Natural S-equol Supplement Alleviates Hot Flushes and Other Menopausal Symptoms in Equol Nonproducing Postmenopausal Japanese Women
As published in the Journal of Women’s Health
A Pilot Study on the Effects of S-equol Compared to Soy Isoflavones on Menopausal Hot Flash Frequency
As published in Menopause
New Equol Supplement for Relieving Menopausal Symptoms: Randomized, Placebo-controlled Trial of Japanese Women

EQUELLE uses a nonhormonal compound to relieve menopause symptoms1-3*†

Naturally derived S-equol binds to estrogen receptors to mimic some but not all of the effects of estrogen by preferentially binding to ER-ß over ER-α without affecting sex and thyroid hormone concentrations.4,5
Estrogen molecules S-equol molecules
 

EQUELLE uses a nonhormonal compound to relieve menopause symptoms1-3*†

 
Naturally derived S-equol binds to estrogen receptors to mimic some but not all of the effects of estrogen by preferentially binding to ER-ß over ER-α without affecting sex and thyroid hormone concentrations.4,5
 
Estrogen molecules S-equol molecules

S-equol is backed by decades of research

 
See the research history behind EQUELLE and the primary active ingredient, S-equol.

Connect with EQUELLE for practice materials including:

Patient education icon
Patient educational materials
Savings icon
Exclusive savings for your patients
Sample icon
7-day samples of equelle
Sample icon
Practice support and additional offerings from Nature Made